Serum FLC and κ:λ ratio on ibrutinib, grouped by κ and λ light-chain restriction
| . | κ clonal CLL . | λ clonal CLL . | ||||
|---|---|---|---|---|---|---|
| κ:λ ratio . | κ FLC, mg/L . | λ FLC, mg/L . | κ:λ ratio . | λ FLC, mg/L . | κ FLC, mg/L . | |
| Normal range | 0.4-1.8 | 5.7-22.2 | 6.6-23.2 | 0.4-1.8 | 5.7-22.2 | 6.6-23.2 |
| Patients | n = 39 | n = 28 | ||||
| Median (IQR) | ||||||
| Pretreatment | 8.8 (2.5-28.6) | 67.1 (23.4-167.0) | 9.5 (6.2-12.2) | 0.2 (0.04-0.4) | 43.6 (27.4-84.9) | 8.7 (1.7-14.8) |
| 6 mo | 1.3 (1.0-1.9) | 14.2 (9.8-28.1) | 11.1 (7.1-15.6) | 0.5 (0.1-0.9) | 15.2 (10.2-21.0) | 9.1 (1.7-15.3) |
| P < .0001 | P < .0001 | P = .0002 | P < .0001 | P < .0001 | P = .7 | |
| 12 mo | 1.2 (0.9-1.7) | 13.0 (10.6-23.6) | 10.9 (7.7-13.8) | 0.7 (0.2-0.9) | 13.8 (8.4-18.1) | 8.6 (2.1-13.1) |
| P < .0001 | P < .0001 | P = .0005 | P < .0001 | P < .0001 | P = .7 | |
| . | κ clonal CLL . | λ clonal CLL . | ||||
|---|---|---|---|---|---|---|
| κ:λ ratio . | κ FLC, mg/L . | λ FLC, mg/L . | κ:λ ratio . | λ FLC, mg/L . | κ FLC, mg/L . | |
| Normal range | 0.4-1.8 | 5.7-22.2 | 6.6-23.2 | 0.4-1.8 | 5.7-22.2 | 6.6-23.2 |
| Patients | n = 39 | n = 28 | ||||
| Median (IQR) | ||||||
| Pretreatment | 8.8 (2.5-28.6) | 67.1 (23.4-167.0) | 9.5 (6.2-12.2) | 0.2 (0.04-0.4) | 43.6 (27.4-84.9) | 8.7 (1.7-14.8) |
| 6 mo | 1.3 (1.0-1.9) | 14.2 (9.8-28.1) | 11.1 (7.1-15.6) | 0.5 (0.1-0.9) | 15.2 (10.2-21.0) | 9.1 (1.7-15.3) |
| P < .0001 | P < .0001 | P = .0002 | P < .0001 | P < .0001 | P = .7 | |
| 12 mo | 1.2 (0.9-1.7) | 13.0 (10.6-23.6) | 10.9 (7.7-13.8) | 0.7 (0.2-0.9) | 13.8 (8.4-18.1) | 8.6 (2.1-13.1) |
| P < .0001 | P < .0001 | P = .0005 | P < .0001 | P < .0001 | P = .7 | |
All P values reflect paired comparisons to pretreatment samples.